You are here

  • Home
  • Archive
  • Volume 10, Issue 1
  • Potential therapies for immune-related adverse events associated with immune checkpoint inhibition: from monoclonal antibodies to kinase inhibition

Article info

Article menu

Download PDFPDF

Review
Potential therapies for immune-related adverse events associated with immune checkpoint inhibition: from monoclonal antibodies to kinase inhibition

Authors

  • Meagan-Helen Henderson Berg Division of Dermatology, McGill University, Montreal, Québec, CanadaDivision of Experimental Medicine, McGill University, Montreal, Québec, CanadaCancer Axis, Lady Davis Institute for Medical Research, Montreal, Québec, Canada PubMed articlesGoogle scholar articles
  • Sonia Victoria del Rincón Division of Experimental Medicine, McGill University, Montreal, Québec, CanadaCancer Axis, Lady Davis Institute for Medical Research, Montreal, Québec, CanadaDepartment of Oncology, Jewish General Hospital and McGill University, Montreal, Québec, CanadaCentre for Translational Research, McGill University, Montreal, Québec, Canada PubMed articlesGoogle scholar articles
  • Wilson H Miller Division of Experimental Medicine, McGill University, Montreal, Québec, CanadaCancer Axis, Lady Davis Institute for Medical Research, Montreal, Québec, CanadaDepartment of Oncology, Jewish General Hospital and McGill University, Montreal, Québec, CanadaCentre for Translational Research, McGill University, Montreal, Québec, CanadaRossy Cancer Network, McGill University, Montreal, Québec, Canada PubMed articlesGoogle scholar articles
  1. Correspondence to Dr Wilson H Miller; wilsonmiller{at}gmail.com; Dr Sonia Victoria del Rincón; sonia.delrincon{at}mcgill.ca
View Full Text

Citation

Henderson Berg M, del Rincón SV, Miller WH
Potential therapies for immune-related adverse events associated with immune checkpoint inhibition: from monoclonal antibodies to kinase inhibition
Journal for ImmunoTherapy of Cancer 2022;10:e003551. doi: 10.1136/jitc-2021-003551

Publication history

  • Accepted December 14, 2021
  • First published January 27, 2022.
Online issue publication 
January 27, 2022

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.